Loading...
Market
Patent Lawsuit Against ProfluentBio Over OpenCRISPR-1 by 2024 End?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Court records, legal news outlets
Story
ProfluentBio Launches OpenCRISPR-1, First AI-Designed Open-Source Gene Editor
Apr 23, 2024, 01:49 AM
ProfluentBio has announced the successful deployment of the first ever AI-designed gene editor, OpenCRISPR-1, marking a significant advancement in genetic engineering. This innovative tool, developed using ProfluentBio's large language models, consists of a Cas9-like protein and guide RNA. The company has decided to freely release the molecules under the OpenCRISPR initiative, aiming to democratize access to cutting-edge gene editing capabilities and accelerate the development of personalized medicine. The release of OpenCRISPR-1 is expected to revolutionize the field of biomedicine by enabling more widespread and ethical use of CRISPR technologies. Coverage of this development has been provided by @nytimes, with further details available in an article by @cademetz.
View original story
Similar markets
Reformulate supply chains • 33%
Seek exemptions • 33%
Challenge the Act legally • 34%
Settled out of court • 33%
In favor of the employee • 33%
In favor of Neuralink • 34%
